Log in

PFSA Profusa, Inc. NASDAQ · United States

Profusa (PFSA) news PFSA convertible notes and merger news

Latest Profusa news

  1. Debt Financing

    Profusa amends Ascent Partners convertible note terms

    Ascent Partners Fund LLC is the holder and collateral agent. The exhibit sets a $0.338 floor, a 150% share reserve and waivers on three later notes, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026.

  2. Debt Financing

    Profusa sells senior secured convertible note to Ascent Partners Fund

    Ascent Partners Fund LLC bought the note as initial purchaser and also acts as collateral agent. The $384,615.38 note was sold for $350,000, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026.

  3. Debt Financing

    Profusa sells another senior secured convertible note to Ascent

    The note has a principal amount of $329,670.33 and was sold for $300,000.00, reflecting original issue discount. Ascent Partners Fund LLC is the initial purchaser.

  4. Listings

    Profusa reports Q2 2026 results and progress on G3 option

    Profusa reported cash of $719,000 at June 30, 2026, and said it expects stockholders' equity of $28.4 million as of July 31, 2026.

  5. Debt Financing

    Profusa issues $714,285.72 senior secured convertible note

    The note has a $650,000.00 purchase price and matures in August 2027. The filing names no placement agent or advisor.

  6. Debt Financing

    Profusa expects about $7 million convertible note alongside diagnostics deal

    Profusa signed a non-binding term sheet to acquire a private diagnostics company that it says had about $111 million of 2025 revenue. The deal would come with an estimated $7 million convertible note at a 7% rate and a 9% original issue discount.

Profusa annual financials

LineFY2025FY2024
Revenue$100,000
Research and development$2.8 million$1.6 million
Net income (loss)-$35.8 million-$9.2 million
Cash from operations-$16.2 million-$2.1 million
Cash and equivalents$1.8 million$191,000

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $719,000.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Profusa

Has Profusa sold convertible notes?

Our latest story on this, dated Oct 15, 2026: "Profusa issues $769,230.77 secured convertible note to Ascent Partners". The story links the filing or release it is based on. Read the story.

Is Profusa involved in a merger or acquisition?

Our latest story on this, dated Jul 27, 2026: "Profusa expects about $7 million convertible note alongside diagnostics deal". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Profusa?

Profusa, Inc. trades under the ticker PFSA on NASDAQ.

Where is Profusa listed?

Profusa, Inc. is listed on NASDAQ.

Which country or territory is Profusa listed under?

Our directory records Profusa, Inc. under United States.

Does aibio.space cover Profusa?

aibio.space lists Profusa, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Profusa profitable?

Profusa, Inc. reported a net loss of $35.8 million for the fiscal year ended Dec 31, 2025, and used $16.2 million of cash in operations, per its annual report to the SEC.

How much does Profusa spend on research and development?

$2.8 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Profusa have?

$719,000 in cash at Jun 30, 2026, per its 10-Q.

What is the latest Profusa (PFSA) stock news?

Our latest story on Profusa, dated Oct 15, 2026: "Profusa issues $769,230.77 secured convertible note to Ascent Partners". The note carries 7% interest, converts at $4.28 a share and matures in October 2027. Source.

Is Profusa at risk of delisting?

Our latest listing story, dated Aug 20, 2026: "Profusa reports Q2 2026 results and progress on G3 option". Profusa reported cash of $719,000 at June 30, 2026, and said it expects stockholders' equity of $28.4 million as of July 31, 2026. Source.

How can I follow Profusa (PFSA) news?

Press Follow on this page to add Profusa to your Following list, or subscribe to the aibio.space newsletter. We have published 7 stories naming Profusa so far, in Debt Financing, Listings.

Investor discussion: Profusa

Members talk about Profusa (PFSA). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Profusa, newest first. Each line links the filing it comes from.

  1. Legal

    Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source

  2. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source

  3. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source

  4. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source

  5. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  6. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  7. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source

  8. Distress

    Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source

  9. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,7.01,8.01,9.01). Source

  10. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source

  11. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source

  12. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  13. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source

  14. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  15. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source

  16. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,3.03,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:PFSA on TradingView.

Listing details

Profusa, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PFSA, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Profusa, Inc.
Ticker
PFSA
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.